Biodexa issues letter to Shareholders

May 14, 2026 Biodexa issues letter to Shareholders Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing innovative products focused on the treatment or prevention of gastrointestinal cancers has today issued the following letter to shareholders explaining the proposals to reorganize the company's share capital at the forthcoming Annual General Meeting. For holders of ADSs, the proposals will impact neither the number of ADSs held nor percentage ownership nor shareholder's rights.

GlobeNewsWire • May 14, 2026

Biodexa Announces Partnership with Syngene To Manufacture MTX240 GMP Clinical Trial Supplies

April 2, 2026 Biodexa Announces Partnership with Syngene To Manufacture MTX240 GMP Clinical Trial Supplies Biodexa Pharmaceuticals PLC (Nasdaq: BDRX) (“Biodexa” or “Company”), a clinical stage biopharmaceutical company developing a clinical stage biopharmaceutical company developing innovative products focused on the treatment or prevention of gastrointestinal cancers, is pleased to announce that it has partnered with Syngene International Ltd (BSE: 539268, NSE: SYNGENE) (“Syngene”) for the manufacture of both MTX240 active pharmaceutical ingredient and dosage form. Commenting, Dan Palmer, Vice President, Technology at Biodexa said “We are delighted to be partnering with Syngene for the second time.

GlobeNewsWire • Apr 2, 2026

Preliminary Results for the Year Ended 31 December 2025

March 27, 2026 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company” or, together with its subsidiaries, the “Group”) Preliminary Results for the Year Ended 31 December 2025 Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical-stage biopharmaceutical company developing innovative products focused on the treatment or prevention of gastrointestinal cancers, announces its audited preliminary results for the year ended 31 December 2025. For more information, please contact: Biodexa Pharmaceuticals PLC Stephen Stamp, CEO Fiona Sharp, CFOTel: +44 (0)29 2048 0180 www.biodexapharma.com About Biodexa The Company's lead development programs include eRapa, under development for Familial Adenomatous Polyposis and Non-Muscle Invasive Bladder Cancer, MTX240 under development for Gastrointestinal Stromal Tumors (GIST) and tolimidone, under development for the treatment of type 1 diabetes.

GlobeNewsWire • Mar 27, 2026

Biodexa Launches Global Early Access Program for eRapa for FAP Patients Through Strategic Partnership with Tanner Pharma Group

March 23, 2026 Biodexa Launches Global Early Access Program for eRapa for FAP Patients Through Strategic Partnership with Tanner Pharma Group Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing innovative products focused on the treatment or prevention of gastrointestinal cancers is pleased to announce that it has entered into a strategic partnership with Tanner Pharma Group to make eRapa available for Familial Adenomatous Polyposis (FAP) patients via an Early Access Program and Named Patient prescribing. This initiative gives clinicians who treat FAP patients the opportunity to prescribe this investigational medicine outside of a clinical trial for the first time.

GlobeNewsWire • Mar 23, 2026

ADR Ratio Change

March 18, 2026 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) ADR Ratio Change Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of rare diseases with unmet medical needs, today announces a ratio change on its American Depositary Receipts (“ADR”) from one (1) ADR representing one hundred thousand (100,000) ordinary shares, to the new ratio of one (1) ADR representing five hundred thousand (500,000) ordinary shares (the "Ratio Change"). The effective date of the Ratio Change is expected to be on or about April 6, 2026.

GlobeNewsWire • Mar 18, 2026

Biodexa Announces Support for Life's a Polyp Foundation First U.S. Patient Advocacy Group for FAP Patients

March 9, 2026 Biodexa Announces Support for Life's a Polyp Foundation First U.S. Patient Advocacy Group for FAP Patients Cardiff, UK – March 9, 2026 – Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing innovative products focused on the treatment or prevention of gastrointestinal cancers, is pleased to recognise Life's a Polyp Foundation on its official launch following an initial financial grant from Biodexa to support the organization's vital work empowering patients with Familial Adenomatous Polyposis (FAP). The Life's a Polyp Foundation, led by dedicated FAP advocate Jenny Jones, marks the first U.S.-based patient advocacy group dedicated exclusively to FAP, providing essential resources, community support, and awareness for patients and families facing this rare genetic condition that causes hundreds of precancerous polyps and carries a near-100% risk of colorectal cancer without intervention.

GlobeNewsWire • Mar 9, 2026

Biodexa Licenses Phase 1 Ready Drug Candidate from Otsuka for Rare Stomach Cancer

MTX240's mechanistic novelty may give it a long-awaited edge in treatments for gastrointestinal stromal tumors (GIST) Meg Flippin, Benzinga Staff Writer CARDIFF, UK / ACCESS Newswire / February 19, 2026 / Biodexa Pharmaceuticals PLC (NASDAQ:BDRX), a clinical-stage biopharmaceutical company developing a pipeline of innovative products for the treatment of rare diseases with an increasing focus on products to treat or prevent gastrointestinal cancers, has added a new Phase 1 ready candidate to its portfolio, this time to target gastrointestinal stromal tumors, or GIST. Several drugs are available to treat GIST, but all ultimately fail when the tumor develops resistance.

Accesswire • Feb 19, 2026

Biodexa Announces Exclusive License of Otsuka's OPB-171775, a potent Phase 1 ready Molecular Glue for GIST

February 4, 2026 Biodexa Announces Exclusive License of Otsuka's OPB-171775, a potent Phase 1 ready Molecular Glue for GIST Novel Mechanism of Action Shown to be Effective in TKI Resistant PDX Models Cardiff, UK – February 4, 2026 – Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of rare diseases with unmet medical needs, today announced the closing of an exclusive license with Otsuka Pharmaceutical Co., Ltd (Otsuka) for OPB-171775. a novel molecular glue intended to be developed for the treatment of gastrointestinal stromal tumours (GIST).

GlobeNewsWire • Feb 4, 2026

Appointment of Fiona Sharp to the Board as Chief Financial Officer and Company Secretary

January 05, 2026 Biodexa Pharmaceuticals PLC Appointment of Fiona Sharp to the Board as Chief Financial Officer and Company Secretary Biodexa Pharmaceuticals PLC (“Biodexa” or “the Company”), (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, is delighted to announce the promotion of Fiona Sharp to Chief Financial Officer and Company Secretary along with her election to the Board of Directors of the Company with immediate effect. Ms Sharp is a senior finance professional having joined the Company as Group Financial Controller in December 2019.

GlobeNewsWire • Jan 5, 2026

Biodexa Announces Pricing of $10 Million Public Offering

December 18, 2025 Biodexa Announces Pricing of $10 Million Public Offering Biodexa Pharmaceuticals PLC, (Nasdaq: BDRX) (“Biodexa” or the “Company”), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, today announced the pricing of a best efforts public offering of an aggregate of (i) 157,000 units (the “ADS Units”), with each unit consisting of (A) one American depositary share (representing 100,000 of the Company's ordinary shares) (“ADSs”), and (B) two Series L warrants, each to purchase one ADS (the “Series L Warrants”), and (ii) 2,891,781 pre-funded units (the “Pre-Funded Units”), with each Pre-Funded Unit consisting of (A) one pre-funded warrant to purchase one ADS and (ii) two Series L Warrants. The combined public offering price of each ADS Unit is $3.28, and the combined public offering price of each Pre-Funded Unit is $3.2799.

GlobeNewsWire • Dec 18, 2025